Skip to main content

Research Repository

Advanced Search

Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection

Pascal, Kristen E.; Coleman, Christopher M.; Mujica, Alejandro O.; Kamat, Vishal; Badithe, Ashok; Fairhurst, Jeanette; Hunt, Charleen; Strein, John; Berrebi, Alexander; Sisk, Jeanne M.; Matthews, Krystal L.; Babb, Robert; Chen, Gang; Lai, Ka-Man V.; Huang, Tammy T.; Olson, William; Yancopoulos, George D.; Stahl, Neil; Frieman, Matthew B.; Kyratsous, Christos A.

Authors

Kristen E. Pascal

CHRISTOPHER COLEMAN CHRISTOPHER.COLEMAN@NOTTINGHAM.AC.UK
Assistant Professor of Infection Immunology

Alejandro O. Mujica

Vishal Kamat

Ashok Badithe

Jeanette Fairhurst

Charleen Hunt

John Strein

Alexander Berrebi

Jeanne M. Sisk

Krystal L. Matthews

Robert Babb

Gang Chen

Ka-Man V. Lai

Tammy T. Huang

William Olson

George D. Yancopoulos

Neil Stahl

Matthew B. Frieman

Christos A. Kyratsous



Abstract

© 2015, National Academy of Sciences. All rights reserved. Traditional approaches to antimicrobial drug development are poorly suited to combatting the emergence of novel pathogens. Additionally, the lack of small animal models for these infections hinders the in vivo testing of potential therapeutics. Here we demonstrate the use of the VelocImmune technology (a mouse that expresses human antibody-variable heavy chains and κ light chains) alongside the VelociGene technology (which allows for rapid engineering of the mouse genome) to quickly develop and evaluate antibodies against an emerging viral disease. Specifically, we show the rapid generation of fully human neutralizing antibodies against the recently emerged Middle East Respiratory Syndrome coronavirus (MERS-CoV) and development of a humanized mouse model for MERS-CoV infection, which was used to demonstrate the therapeutic efficacy of the isolated antibodies. The VelocImmune and VelociGene technologies are powerful platforms that can be used to rapidly respond to emerging epidemics.

Citation

Pascal, K. E., Coleman, C. M., Mujica, A. O., Kamat, V., Badithe, A., Fairhurst, J., …Kyratsous, C. A. (2015). Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection. Proceedings of the National Academy of Sciences, 112(28), 8738-8743. https://doi.org/10.1073/pnas.1510830112

Journal Article Type Article
Acceptance Date Jun 2, 2015
Online Publication Date Jun 29, 2015
Publication Date Jul 14, 2015
Deposit Date Dec 17, 2019
Journal Proceedings of the National Academy of Sciences of the United States of America
Print ISSN 0027-8424
Electronic ISSN 1091-6490
Publisher National Academy of Sciences
Peer Reviewed Peer Reviewed
Volume 112
Issue 28
Pages 8738-8743
DOI https://doi.org/10.1073/pnas.1510830112
Public URL https://nottingham-repository.worktribe.com/output/3590119